There has been recent discussion about a possible link between Aleve (naproxen sodium) and cardiac problems over time, similar to the types associated previously with Vioxx and other COX2 inhibitors.
This wasn't lumping naproxen with the COX2 inhibitors: it was associating Vioxx with them. However, if it was unclear, I'm glad you made the point.
There were several things that weren't pointed out very often in the painkiller furor. For Vioxx and most others, the raised risk only came after six months of continuous use. And it only came with higher dosages. The lower dosage of Vioxx didn't produce the problem even with extended use. Nonetheless, Vioxx was voluntarily withdrawn from the market, and no longer helps anyone. Bextra was also withdrawn, although its profile wasn't as good as the others anyway. Celebrex was also slammed, but the FDA has allowed it to be continued because the risk/benefit ratio is still favorable overall, as long as the patients are aware of the potential for added risk.
COX2-specific inhibitors do generally need to build up in the system to have their most useful effect (which is why you wouldn't take them with a headache: they have a delayed effect, needing a day or two of taking them to start achieving results). However, there could easily be a schedule that allows the drug to flush out of your system every so often, if higher and continuous doses are needed.
You should be aware that the jury is still out for many of the nonspecific NSAIDS as well. We may face the prospect of losing them as well:
From Merck (
http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp)
The U.S. Food and Drug Administration and Health Canada have concluded that an increased risk of serious thrombotic cardiovascular adverse events is associated with all COX 2 selective NSAIDs. In addition, these regulatory agencies concluded that, although long-term placebo-controlled data are not available for non-selective NSAIDS, the current data suggests that COX 2 selective NSAIDs and non-selective NSAIDs have similar cardiovascular risk profiles.
From the FDA (
http://www.fda.gov/cder/drug/advisory/COX2.htm)
A number of non-selective NSAIDs (prescription and non-prescription (over-the-counter (OTC)) are approved for marketing in the United States....
Long-term controlled clinical trials have not been conducted with most of these NSAIDs. However, the available data suggest that use of these drugs may increase CV risk. It is very difficult to draw conclusions about the relative CV risk among the COX-2 selective and non-selective NSAIDs with the data available.
All sponsors of non-selective NSAIDs will be asked to conduct and submit to FDA a comprehensive review and analysis of available controlled clinical trial databases pertaining to their NSAID product(s) to which they have access to further evaluate the potential for increased CV risk.
Again, I'm not defending these drugs specifically. My concern is that they and others were useful to many people, and in a press-fed atmosphere of emotional backlash rather than reason, any value that these medicines might bring with altered administration profiles is destroyed and lost, like a downtown store being smashed and looted to no one's real gain.
Now, doctors are adding more medications for their patients with the drug-eluting stents, such as Plavix, which carry their own risks. Are these risks being balanced against the stent's risks, or is the use of these drugs just knee-jerk appeasement for their insurance companies? Are they responding to their patients' true needs, or to pacify public concern that has been fomented by the press?
We know that politicians, who have free access to expert opinions and massive amounts of study data, screw things up badly enough when
they try to regulate things. So why should we trust a kangaroo court of half-informed reporters to do the same thing simply by manipulating public opinion? I've watched a number of reports on heart valve issues, and it becomes plain over time that the health news press frequently doesn't have a clue what they're talking about...
Best wishes,